{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:40:44Z","timestamp":1788921644617,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 DK084149"],"award-info":[{"award-number":["R01 DK084149"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 DK070941"],"award-info":[{"award-number":["R01 DK070941"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01 DK116041"],"award-info":[{"award-number":["U01 DK116041"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1053\/j.ackd.2019.01.003","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T19:01:21Z","timestamp":1555959681000},"page":"131-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Impact of APOL1 on Chronic Kidney Disease and Hypertension"],"prefix":"10.1053","volume":"26","author":[{"given":"Todd W.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry I.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ackd.2019.01.003_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2215\/CJN.09030817","article-title":"Lessons from CKD-related genetic association studies-Moving Forward","volume":"13","author":"Limou","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.01.003_bib2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajhg.2017.05.004","article-title":"Genetic-variation-driven gene-Expression changes Highlight genes with important functions for kidney disease","volume":"100","author":"Ko","year":"2017","journal-title":"Am J Hum Genet"},{"issue":"9455","key":"10.1053\/j.ackd.2019.01.003_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2019.01.003_bib4","series-title":"Epidemiology of kidney disease in the United States","year":"2016"},{"issue":"2","key":"10.1053\/j.ackd.2019.01.003_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0272-6386(95)90001-2","article-title":"The link between hypertension and nephrosclerosis","volume":"25","author":"Freedman","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2019.01.003_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrneph.2015.172","article-title":"Hypertension-attributed nephropathy: what's in a name?","volume":"12","author":"Freedman","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"5993","key":"10.1053\/j.ackd.2019.01.003_bib7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"issue":"3","key":"10.1053\/j.ackd.2019.01.003_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene","volume":"128","author":"Tzur","year":"2010","journal-title":"Hum Genet"},{"issue":"22","key":"10.1053\/j.ackd.2019.01.003_bib9","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.ackd.2019.01.003_bib10","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"10","key":"10.1053\/j.ackd.2019.01.003_bib11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ackd.2019.01.003_bib12","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.01.003_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.7326\/M16-2966","article-title":"Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in Persons without kidney disease: a secondary analysis of a randomized trial","volume":"167","author":"Beddhu","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.01.003_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ekir.2017.03.008","article-title":"APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial","volume":"2","author":"Freedman","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ackd.2019.01.003_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/ki.2014.254","article-title":"Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial","volume":"87","author":"Langefeld","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ackd.2019.01.003_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.semnephrol.2017.07.006","article-title":"Apolipoprotein L1 gene effects on kidney Transplantation","volume":"37","author":"Freedman","year":"2017","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.01.003_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/ki.2012.263","article-title":"Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans","volume":"83","author":"Lipkowitz","year":"2013","journal-title":"Kidney Int"},{"issue":"23","key":"10.1053\/j.ackd.2019.01.003_bib18","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.01.003_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/ki.1997.29","article-title":"Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American study of kidney disease (AASK) trial. AASK Pilot study investigators","volume":"51","author":"Fogo","year":"1997","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2019.01.003_bib20","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2017.01.040","article-title":"Apolipoprotein L1 variants and blood pressure Traits in African Americans","volume":"69","author":"Nadkarni","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1053\/j.ackd.2019.01.003_bib21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00467-014-3031-0","article-title":"Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease","volume":"30","author":"Anyaegbu","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.01.003_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/ATVBAHA.115.305970","article-title":"APOL1 genotype, kidney and cardiovascular disease, and death in older adults","volume":"36","author":"Mukamal","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1053\/j.ackd.2019.01.003_bib23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCRESAHA.114.302347","article-title":"Increased burden of cardiovascular disease in carriers of APOL1 genetic variants","volume":"114","author":"Ito","year":"2014","journal-title":"Circ Res"},{"issue":"1","key":"10.1053\/j.ackd.2019.01.003_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ki.2014.255","article-title":"APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes","volume":"87","author":"Freedman","year":"2015","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.01.003_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.kint.2016.04.027","article-title":"APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume","volume":"90","author":"Freedman","year":"2016","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ackd.2019.01.003_bib26","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1681\/ASN.2015070763","article-title":"Race, APOL1 risk, and eGFR decline in the general population","volume":"27","author":"Grams","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.01.003_bib27","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.kint.2017.03.028","article-title":"APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults","volume":"92","author":"Chen","year":"2017","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2019.01.003_bib28","doi-asserted-by":"crossref","first-page":"e007199","DOI":"10.1161\/JAHA.117.007199","article-title":"Association between APOL1 genotypes and risk of cardiovascular disease in MESA (Multi-Ethnic study of atherosclerosis)","volume":"6","author":"Chen","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1053\/j.ackd.2019.01.003_bib29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ndt\/gfv229","article-title":"APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans","volume":"31","author":"Gutierrez","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ackd.2019.01.003_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.2017060658","article-title":"APOL1 genotype and renal function of black living donors","volume":"29","author":"Doshi","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.01.003_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ki.2012.369","article-title":"Hypertension-misattributed kidney disease in African Americans","volume":"83","author":"Skorecki","year":"2013","journal-title":"Kidney Int"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519300035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519300035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:01:24Z","timestamp":1761548484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519300035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1548559519300035"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.01.003","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of APOL1 on Chronic Kidney Disease and Hypertension","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}